Cargando…

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: Nivolumab-related serious/fatal adverse events

BACKGROUND: Nivolumab, an immune checkpoint inhibitor, has revolutionized the treatment of many cancers. Due to its novel mechanisms of action, nivolumab induces a distinct profile of adverse events. Currently, the incidence and risk of developing serious adverse events (SAEs) or fatal adverse event...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Bin, Zhao, Hong, Zhao, Jiaxin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171173/ https://www.ncbi.nlm.nih.gov/pubmed/30285872 http://dx.doi.org/10.1186/s40425-018-0421-z

Ejemplares similares

Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
por: Zhao, Bin, et al.
Publicado: (2019)

Serious Neurological Adverse Events of Ceftriaxone
por: Lacroix, Clémence, et al.
Publicado: (2021)

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
por: Zhou, Shi, et al.
Publicado: (2019)

Steven-Johnson Syndrome: A Rare but Serious Adverse Event of Nivolumab Use in a Patient With Metastatic Gastric Adenocarcinoma
por: Saad, Eltaib, et al.
Publicado: (2022)

Adverse events induced by nivolumab and ipilimumab combination regimens
por: Somekawa, Kohei, et al.
Publicado: (2022)

Sjögren's Syndrome as an Immune-related Adverse Event of Nivolumab Treatment for Gastric Cancer
por: Higashi, Tetsuo, et al.
Publicado: (2020)

Identification of serious, unpredictable adverse events with tocilizumab
Publicado: (2020)

Serious adverse events associated with yellow fever vaccine
por: de Menezes Martins, Reinaldo, et al.
Publicado: (2015)

Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies
por: Les, Iñigo, et al.
Publicado: (2021)

Clinical picture and outcome of Serious Adverse Events in the treatment of Onchocerciasis
por: Awadzi, Kwablah
Publicado: (2003)

Analysis of serious adverse event: Writing a narrative
por: Nambiar, Indu
Publicado: (2018)

Risk of Adverse Events in Cancer Patients Receiving Nivolumab With Ipilimumab: A Meta-Analysis
por: Zhao, Xin, et al.
Publicado: (2022)

Immune-related adverse events and prognosis in patients with upper gastrointestinal cancer treated with nivolumab
por: Hara, Yoshihiro, et al.
Publicado: (2022)

Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer
por: Zhao, Bin, et al.
Publicado: (2020)

Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma
por: Gautron Moura, Bianca, et al.
Publicado: (2022)

A Cancer Patient’s Experience With a Rare But Serious Adverse Event
por: RayChaudhury, Amlan
Publicado: (2019)

Serious adverse events and coping strategies of CAR-T cells in the treatment of malignant tumors
por: Chen, Xiujin, et al.
Publicado: (2022)

Influenza Vaccination of Pregnant Women and Serious Adverse Events in the Offspring
por: Donzelli, Alberto
Publicado: (2019)

Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab
por: Masuda, Ken, et al.
Publicado: (2019)

Antipsychotics-Associated Serious Adverse Events in Children: An Analysis of the FAERS Database
por: Kimura, Goji, et al.
Publicado: (2015)

Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database
por: Sonawane, Kalyani B., et al.
Publicado: (2018)

An HIV-infected Patient with No Serious Adverse Events after Overdosing on Raltegravir
por: Hosoda, Tomohiro, et al.
Publicado: (2019)

Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events
por: Imafuku, Keisuke, et al.
Publicado: (2017)

Rare Adverse Events Related to Nivolumab, an Immune Checkpoint Inhibitor: A Case Series
por: Ganta, Nagapratap, et al.
Publicado: (2022)

Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis
por: Holmøy, Trygve, et al.
Publicado: (2019)

Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis
por: Liu, Tingting, et al.
Publicado: (2020)

Depression and anxiety in cancer patient enrolled in clinical trials with serious adverse events
por: Peng, Zhen, et al.
Publicado: (2023)

Frequency of pre-treatment may not increase the immune-related adverse events of RCC patients treated with nivolumab
por: Mizutani, Kosuke, et al.
Publicado: (2021)

Evaluation of lung adverse events with nivolumab using the spontaneous reporting system in Japan
por: Kanbayashi, Yuko, et al.
Publicado: (2023)

Serious Cardiovascular Adverse Events Reported with Intravenous Sedatives: A Retrospective Analysis of the MedWatch Adverse Event Reporting System
por: Duprey, Matthew S., et al.
Publicado: (2019)

Surveillance of serious adverse events following immunization in resource poor settings
por: Breugelmans, Gabrielle J, et al.
Publicado: (2011)

Serious adverse event: late neurotropic disease associated with yellow fever vaccine
por: de Oliveira, Henrique Souza Barros, et al.
Publicado: (2020)

Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients—Literature Review
por: Dudzińska, Marta, et al.
Publicado: (2020)

Incidence of Ipilimumab-Related Serious Adverse Events in Patients with Advanced Cancer: A Meta-Analysis
por: Guo, Chang-Ying, et al.
Publicado: (2019)

Serious adverse events of cell therapy for respiratory diseases: a systematic review and meta-analysis
por: Zhao, Runzhen, et al.
Publicado: (2017)

Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab
por: Yamauchi, Ichiro, et al.
Publicado: (2019)

Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review
por: Ouyang, Tao, et al.
Publicado: (2021)

Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS)
por: Zhao, Ying, et al.
Publicado: (2022)

Overlap between adverse events (AEs) and serious adverse events (SAEs): a case study of a phase III cancer clinical trial
por: James, Elizabeth C., et al.
Publicado: (2020)

Meta-analysis of incidence and risk of severe adverse events and fatal adverse events with crizotinib monotherapy in patients with ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_c1u3f9s4cqqjt84bv7cck32blg